Document › Details
PerkinElmer, Inc.. (3/30/12). "Press Release: PerkinElmer Highlights Innovative Solutions for Enabling Personalized Medicine in Cancer Research at AACR 2012". Waltham, MA.
|Organisation||PerkinElmer Inc. (NYSE: PKI)|
|Person||Hrusovsky, Kevin (Quanterix 201507 CEO before PerkinElmer + Caliper)|
|Person 2||Connolly, Amanda L. (Edelman 201107)|
At the American Association for Cancer Research 2012 Annual Meeting (Booth #2306), PerkinElmer, Inc., a global leader focused on improving the health and safety of people and the environment, today announced that it will be showcasing numerous solutions, posters and knowledge-sharing events in support of cancer-focused personalized medicine research.
"PerkinElmer remains committed to the fight against cancer through enabling personalized medicine solutions that allow researchers to find, understand, and act upon the causes and processes of the disease," said Kevin Hrusovsky, President, Life Sciences & Technology, PerkinElmer. "We are passionate about helping academic, biopharma and clinical researchers to achieve new insights for discovering advanced therapeutics and diagnostics to reduce the threat of cancer. Our solutions in Next Generation Sequencing, advanced cellular, in vitro and in vivo imaging, automation instrumentation, and reagent technologies, provide researchers the critical tools they need to combat this deadly disease."
On the evening of Tuesday, April 3, PerkinElmer will be hosting an event, entitled
"The Revolutionizing Medicine Rock 'n' Roll Reception," featuring distinguished speakers who are committed to the fight against cancer, discussing how personalized medicine is changing research and treatment of the disease. The event will also feature performances by Molecular Groove, the PerkinElmer band.
Tuesday, April 3, 6:30 PM - 10:30 PM
Hyatt Regency McCormick Place, Regency Ballroom
Featured speakers at the event include clinical, academic and industry thought leaders in personalized medicine for cancer, such as:
> Raju Kucherlapati Ph.D., Professor of Genetics and Medicine, Harvard University, who will speak on "Personalized Medicine in Cancer"
> James P. Basilion, Ph.D., Associate Professor, Departments of Radiology, Biomedical Engineering, and Pathology, Case Western Reserve University, whose discussion topic is "Defining the Cutting Edge"
> Kevin Hrusovsky, President, Life Sciences & Technology, PerkinElmer, who will present on "Next Generation Innovations Enabling an Advancement in Health"
PerkinElmer solutions for enabling personalized medicine-based cancer research on display at AACR 2012 include:
> The NGS Express™ Automated Liquid Handling Workstation - a compact flexible and easy-to-use library prep system for benchtop sequencers that offers efficient sample preparation for up to 24 Next Generation Sequencing libraries, and eliminates the need for time-consuming protocol development.
> FolateRSense™ and TLectinSense™ Fluorescent Preclinical Imaging Agents, designed to be used by in vivo imaging systems, and for the quantitation and longitudinal study of tumor growth and vascularization.
> AlphaLISA® cellular epigenetics detection kits, a no-wash homogeneous proximity immunoassay to detect specific methylation and acetylation states for epigenetics research.
PerkinElmer instruments and software featured at AACR include:
> LabChip® GX Nucleic Acid Separation System
> JANUS® Automated Liquid Handling Workstation
> Operetta® High Content Imaging System
> VectraTM 2 Automated Slide Imaging system
> FMT® Quantitative Fluorescence Tomography Imaging System
> EnSpire® Multimode Plate Reader
> ColumbusTM Image Storage and Analysis Software
> UltraVIEW® Vox 3D Live Cell Imaging System
> Volocity® 3D Image Analysis Software
> Geospiza® Genesifter® Genetic Analysis Software
PerkinElmer poster presentations at AACR 2012 include:
Sunday, April 1: 1:00 pm - 5:00 pm
236/30 - Hall F, Section 8 - Characterizing cellular signal transduction cross-talk using in-cell kinase screen
382/30 - Hall F, Section 13 - In-vivo imaging of lung cancer using tumor homing peptide coated nanoparticles
Monday, April 2: 8:00 am - 12:00 pm
1319/6 - Hall F, Section 11 - Establishment & characterization of fresh primary human colorectal tumor implants
Monday, April 2: 1:00 pm - 5:00 pm
2448/21 - Hall F, Section 16 - Development of a red fluorescent labeled agent for assessing HER2 expression in vitro & in vivo
2444/17 - Hall F, Section 16 - Non-invasive FMT quantification of folate receptor expression in mouse tumor xenografts with a new near-infrared fluorescent folate agent
Tuesday, April 3: 8:00 am - 12:00 pm
3879/2 - Hall F, Section 34 - High-throughput, homogeneous in cyto assays to monitor histone H3 post-translational modifications
3880/3 - Hall F, Section 34 - Application of tyramide signal amplification technology to high content analysis of cellular kinase translocation assays
Tuesday, April 3: 1:00 pm - 5:00 pm
3949/16 - Hall F, Section 1 - In vivo imaging of tumor hypoxia by a new near-infrared fluorescent carbonic anhydrase IX-targeted agent
4292/8 - Hall F, Section 14 - In vivo & in vitro imaging of Cyclooxygenase-2 in tumor
4050/5 - Hall F, Section 5 - Monitoring of melanoma therapy with quantitative tissue cytometry of a panel of apoptosis markers
Wednesday, April 4: 8:00 am - 12:00 pm
LB-511 - Hall F, Section 38 - In vivo imaging of tumor vasculature with a novel near infra-red lectin agent
About PerkinElmer, Inc.
PerkinElmer, Inc. is a global leader focused on improving the health and safety of people and the environment. The Company reported revenue of approximately $1.9 billion in 2011, has about 7,000 employees serving customers in more than 150 countries, and is a component of the S&P 500 Index. Additional information is available through 1-877-PKI-NYSE, or at www.perkinelmer.com.
# # #
Corporate Public Relations Manager
Phone: (781) 663-5602
Amanda L. Connolly
Edelman (on behalf of PerkinElmer, Inc.)
Direct: (404) 832-6785
Record changed: 2016-03-19
More documents for PerkinElmer (Group)
-  PerkinElmer, Inc.. (2/16/17). "Press Release: PerkinElmer to Present at Barclays Capital Global Healthcare Conference". Waltham, MA....
-  PerkinElmer, Inc.. (2/2/17). "Press Release: PerkinElmer Announces Financial Results for Fourth Quarter and Full Year 2016". Waltham, MA....
-  PerkinElmer, Inc.. (1/23/17). "Press Release: PerkinElmer's NexION 2000 ICP-MS Provides Industry-leading Versatility for Trace Elemental Analyses". Waltham, MA....
-  PerkinElmer, Inc.. (1/9/17). "Press Release: PerkinElmer to Acquire Tulip Diagnostics Private Limited in India". Waltham, MA....
-  PerkinElmer, Inc.. (12/22/16). "Press Release: PerkinElmer to Sell Medical Imaging Business to Varian Medical Systems". Waltham, MA....
-  PerkinElmer, Inc.. (12/14/16). "Press Release: PerkinElmer to Present at J.P. Morgan 35th Annual Healthcare Conference". Waltham, MA....
-  PerkinElmer, Inc.. (11/21/16). "Press Release: PerkinElmer to Present at Citi Global Healthcare Conference". Waltham, MA....
-  PerkinElmer, Inc.. (11/14/16). "Press Release: PerkinElmer to Present at Piper Jaffray Healthcare Conference". Waltham, MA....
-  PerkinElmer, Inc.. (11/7/16). "Press Release: PerkinElmer Announces Financial Results for the Third Quarter of 2016". Waltham, MA....
-  PerkinElmer, Inc.. (10/26/16). "Press Release: PerkinElmer Board Declares Quarterly Dividend". Waltham, MA....
To subscribe to our free, monthly mass spectrometry newsletter, please send an e-mail to email@example.com and simply fill the subject line with the word »MSC newsletter«
To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]